N-Zyme Biomedical Closes $4.6 Million Series A

N-Zyme Biomedical has closed about $4.6 million in Series A funding.

The round included support from healthcare professionals, entrepreneurs, a venture capital group, and strategic backers.

Proceeds will be used to advance Phase 2 programs and develop the company’s pepsin inhibitor platform.

The funding helps push a potential new treatment approach for reflux disease, an area with unmet medical need.